ImmunoPrecise in $8M deal with biotech firm for ADCs in cancer treatments

ImmunoPrecise Antibodies (IPA) announces a strategic partnership with a leading biotechnology company with a multi-billion-dollar market capitalization to advance the discovery and development of Antibody-Drug Conjugates or ADCs and bispecific antibodies for the treatment of cancer. This collaboration focuses on leveraging contract research expertise while integrating IPA’s proprietary B-cell Select platform and artificial intelligence-driven discovery capabilities to enhance the efficiency and precision of therapeutic development. Under the terms of the agreement, the partnership will encompass the discovery, lead characterization, optimization, and preclinical-grade production of multiple antibody-based therapeutics, with a focus on developing highly selective and effective cancer treatments. IPA’s proprietary multi-omics AI-driven modeling and discovery platform, combined with its B-cell Select technology, will be integrated at key stages to optimize therapeutic selection and accelerate lead development. The agreement, valued at an initial $8M with the potential to expand to $10M based on program progression, will span 18 to 24 months, integrating artificial intelligence across the workflow to enhance discovery and optimization. “With the purchase order … This collaboration highlights IPA’s role in shaping the future of next-generation biologics